Literature DB >> 26192781

Targeting growth factor supply in keratopathy treatment: comparison between maternal peripheral blood and cord blood as sources for the preparation of topical eye drops.

Piera Versura1, Marina Buzzi2, Giuseppe Giannaccare1, Adriana Terzi2, Michela Fresina1, Claudio Velati2, Emilio C Campos1.   

Abstract

BACKGROUND: Epitheliotrophic growth factors (GF) can be supplied topically to patients with severe keratopathy through a variety of blood-derived products. We compared GF content in adult peripheral blood serum (PB-S) and cord blood serum (CB-S) as potential sources of GF. To limit inter-individual variability the assessment was performed in maternal-child pairs at the time of delivery.
MATERIAL AND METHODS: The amounts of epidermal GF (EGF), insulin-like GF (IGF), transforming GF-beta (TGF-β), vascular endothelial GF (VEGF) in CB units collected from the umbilical vein and PB from mothers (each group n=30) were estimated by enzyme-linked immunosorbent assays. Obstetric characteristics and haematological data were recorded from the archives of the Emilia Romagna Cord Blood Bank. Statistical evaluations were performed by Wilcoxon's test and correlations between variables were determined using Spearman's (ρ) coefficient; p-values <0.05 were considered statistically significant.
RESULTS: EGF, TGF-β and VEGF levels were significantly higher in CB-S than in PB-S (median 1,254.4 vs 646.0 pg/mL, 51.3 vs 38.4 μg/mL and 686.8 vs 30 pg/mL, respectively; all p<0.0001) whereas IGF content was significantly higher in PB-S than in CB-S (159.9 vs 53.5 pg/mL, respectively; p<0.0001). In CB-S, the CD34(+) cell concentration appeared to be related to EGF, IGF and TGF-β levels whereas white blood cell count appeared to be related to EGF and TGF-β levels. VEGF levels showed no relation to the haematological parameters considered. Platelet counts were not related to GF level in either CB or PB. DISCUSSION: The GF content in the two blood sources was different, with CB containing larger amounts. Each GF selectively regulates cellular processes involved in corneal healing, so the use of PB or CB should be targeted to supply specific GF on the basis of the type and severity of the keratopathy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26192781      PMCID: PMC4781782          DOI: 10.2450/2015.0020-15

Source DB:  PubMed          Journal:  Blood Transfus        ISSN: 1723-2007            Impact factor:   3.443


  66 in total

Review 1.  Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007).

Authors: 
Journal:  Ocul Surf       Date:  2007-04       Impact factor: 5.033

2.  Allogeneic serum eye drops for the treatment of persistent corneal epithelial defect.

Authors:  C-C Chiang; W-L Chen; J-M Lin; Y-Y Tsai
Journal:  Eye (Lond)       Date:  2008-01-11       Impact factor: 3.775

3.  Therapeutic effect of umbilical cord serum eyedrops for the treatment of dry eye associated with graft-versus-host disease.

Authors:  K C Yoon; I Y Jeong; S K Im; Y G Park; H J Kim; J Choi
Journal:  Bone Marrow Transplant       Date:  2007-01-08       Impact factor: 5.483

4.  Application of umbilical cord serum eyedrops for the treatment of neurotrophic keratitis.

Authors:  Kyung-Chul Yoon; In-Cheon You; Seong-Kyu Im; Tae-Sun Jeong; Yeoung-Geol Park; Jin Choi
Journal:  Ophthalmology       Date:  2007-03-26       Impact factor: 12.079

5.  The effect of growth factor signaling on keratocytes in vitro and its relationship to the phases of stromal wound repair.

Authors:  Latia Etheredge; Bradley P Kane; John R Hassell
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-02-21       Impact factor: 4.799

6.  [Subconjunctival application of plasma platelet concentrate in the treatment of ocular burns. Preliminary results].

Authors:  R Márquez-de-Aracena; I Montero-de-Espinosa; M Muñoz; G Pereira
Journal:  Arch Soc Esp Oftalmol       Date:  2007-08

7.  Comparison of autologous serum and umbilical cord serum eye drops for dry eye syndrome.

Authors:  Kyung-Chul Yoon; Hwan Heo; Seong-Kyu Im; In-Cheon You; Yoon-Ha Kim; Yeoung-Geol Park
Journal:  Am J Ophthalmol       Date:  2007-05-09       Impact factor: 5.258

8.  IGF-1 released by corneal epithelial cells induces up-regulation of N-cadherin in corneal fibroblasts.

Authors:  Ji-Ae Ko; Ryoji Yanai; Teruo Nishida
Journal:  J Cell Physiol       Date:  2009-10       Impact factor: 6.384

9.  Allogeneic serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease.

Authors:  Chun-Chi Chiang; Jane-Ming Lin; Wen-Lu Chen; Yi-Yu Tsai
Journal:  Cornea       Date:  2007-08       Impact factor: 2.651

10.  Subconjunctival application of regenerative factor-rich plasma for the treatment of ocular alkali burns.

Authors:  Rafael Marquez De Aracena Del Cid; Ignacio Montero De Espinosa Escoriaza
Journal:  Eur J Ophthalmol       Date:  2009 Nov-Dec       Impact factor: 1.922

View more
  12 in total

1.  Ophthalmic manifestations of Paederus dermatitis.

Authors:  Pawan Prasher; Mandeep Kaur; Shakeen Singh; Harpreet Kaur; Madhu Bala; Silonie Sachdeva
Journal:  Int Ophthalmol       Date:  2016-09-15       Impact factor: 2.031

2.  Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-Endoret) eye-drops.

Authors:  Ronald Mauricio Sanchez-Avila; Jesus Merayo-Lloves; Ana Cristina Riestra; Luis Fernandez-Vega Cueto; Eduardo Anitua; Leire Begoña; Francisco Muruzabal; Gorka Orive
Journal:  Int Ophthalmol       Date:  2017-06-15       Impact factor: 2.031

3.  Cord Blood Serum (CBS)-Based Eye Drops Modulate Light-Induced Neurodegeneration in Albino Rat Retinas.

Authors:  Stefano Di Marco; Serena Riccitelli; Mattia Di Paolo; Emilio Campos; Marina Buzzi; Silvia Bisti; Piera Versura
Journal:  Biomolecules       Date:  2020-04-28

Review 4.  Neurotrophic keratitis: current challenges and future prospects.

Authors:  Piera Versura; Giuseppe Giannaccare; Marco Pellegrini; Stefano Sebastiani; Emilio C Campos
Journal:  Eye Brain       Date:  2018-06-28

Review 5.  Blood-Based Treatments for Severe Dry Eye Disease: The Need of a Consensus.

Authors:  Federico Bernabei; Matilde Roda; Marina Buzzi; Marco Pellegrini; Giuseppe Giannaccare; Piera Versura
Journal:  J Clin Med       Date:  2019-09-17       Impact factor: 4.241

Review 6.  Treatment of Non-Infectious Corneal Injury: Review of Diagnostic Agents, Therapeutic Medications, and Future Targets.

Authors:  Deanna H Dang; Kamran M Riaz; Dimitrios Karamichos
Journal:  Drugs       Date:  2022-01-13       Impact factor: 9.546

7.  Impact of blood source and component manufacturing on neurotrophin content and in vitro cell wound healing.

Authors:  Sabrina Valente; Nico Curti; Enrico Giampieri; Vanda Randi; Chiara Donadei; Marina Buzzi; Piera Versura
Journal:  Blood Transfus       Date:  2021-08-03       Impact factor: 5.752

8.  The use of autologous serum for the treatment of ocular surface disease at a Swedish tertiary referral center.

Authors:  Joanna von Hofsten; Maria Egardt; Madeleine Zetterberg
Journal:  Int Med Case Rep J       Date:  2016-03-02

9.  Topical Treatment with Cord Blood Serum in Glaucoma Patients: A Preliminary Report.

Authors:  Emilio Campos; Piera Versura; Giuseppe Giannaccare; Adriana Terzi; Silvia Bisti; Stefano Di Marco; Marina Buzzi
Journal:  Case Rep Ophthalmol Med       Date:  2018-07-25

Review 10.  Umbilical Cord Blood and Serum for the Treatment of Ocular Diseases: A Comprehensive Review.

Authors:  Giuseppe Giannaccare; Adriano Carnevali; Carlotta Senni; Laura Logozzo; Vincenzo Scorcia
Journal:  Ophthalmol Ther       Date:  2020-02-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.